Analyst Forecasts For Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Are Surging Higher

Simply Wall StNov 20 06:46 ET

Sangamo Stock Climbs 12% Post-market on FDA Update for ST-503

Seeking AlphaNov 19 16:51 ET

Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment

WSJNov 19 16:41 ET

Sangamo Therapeutics Gets FDA Clearance Of IND Application For ST-503 For Treatment Of Idiopathic Small Fiber Neuropathy

BenzingaNov 19 16:16 ET

Express News | Sangamo Therapeutics Inc - to Initiate Phase 1/2 Study for St-503 in Mid-2025

ReutersNov 19 16:15 ET

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

BusinesswireNov 19 16:15 ET